McKesson Completes About $2.25 Billion Precision Medicine Group Deal

McKesson reported Q2 revenue growth in Prescription Technology Solutions (10% to $1.5B) and Medical-Surgical Solutions (5% to $3.1B). The company acquired Precision Medicine Group for $2.25B, expecting $0.10-$0.20 EPS accretion in 2027. It also agreed to invest $1.4B in Option Care Health. McKesson forecasts 6-10% revenue growth and 12-16% operating profit growth for 2027, with $5B in share repurchases. Executives noted uncertainty around 340B drug pricing program changes.

McKesson (MCK) stock has shown a low correlation with the S&P 500, with a beta of -0.17 over the past year. While it did not deepen losses on average market down days, its volatility was higher at 31.6%. The company's revenue is primarily from its North American Pharmaceutical segment, and it has recently acquired Precision Medicine Group and agreed to a stake in Option Care Health.

McKesson (MCK) reported Q2 2027 earnings, highlighting investments in employee programs and strategic acquisitions. The company acquired Precision Medicine Group to advance its oncology and biopharma services, and plans to invest in Option Care Health. McKesson also extended its distribution agreement with CVS Health. The company reported strong market trends and growth across its platforms, with a focus on technology and automation to enhance services.

McKesson (MCK) reported Q2 revenue of $110.96B (+8% YoY) and adjusted EPS of $11.68, beating estimates. It raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40. The company extended a drug distribution deal with CVS Health and plans to buy 49% of Option Care Health for $1.4B. McKesson also completed its acquisition of Precision Medicine Group and announced plans to separate its medical-surgical solutions segment.

McKesson Corp (MCK) raised fiscal 2027 adjusted EPS guidance to $45.60-$46.40, citing 8% revenue growth to $111 billion in Q2. The company acquired Precision Medicine Group for $2.25 billion, extending oncology capabilities. Challenges include lower branded pharmaceutical pricing and medical-surgical segment profit decline. Management discussed strategic investments and long-term growth targets.

McKesson reported fiscal Q2 2027 revenue of $110.96B, up from $103.15B a year earlier, with net income of $1.22B and EPS of $10.44. The company recorded $221M in restructuring charges for the six-month period. Gross profit rose to $3.96B, while operating income increased to $1.60B. Share buybacks reduced the weighted-average diluted shares, supporting per-share results. The company faces risks related to opiate litigation and rising interest expenses.